Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
News|Articles|May 15, 2014
- Pharmaceutical Technology-05-15-2014
- Volume 2014 eBook
- Issue 2
Continuous Bioprocessing Challenges
What challenges do biopharmaceutical manufacturers face when deciding to move from a fed batch process to a continuous process?
Advertisement
What challenges do biopharmaceutical manufacturers face when deciding to move from a fed batch process to a continuous process? Stéphanie Dubois, cell culture laboratory manager and application specialist at Pall Life Sciences, describes challenges and explains how alternative types of perfusion bioreactors can simplify the process.
Download
.
Articles in this issue
over 12 years ago
Potential Benefits Drive Interest in Continuous Manufacturingover 12 years ago
Optimizing the Sterilization of Liquids in Sealed Containersover 12 years ago
Using Modular Systems in Biopharmaceutical Manufacturingover 12 years ago
Determining Protein Oxidation Induced During Fill-Finish Operationsover 12 years ago
Single-Use Technology in Parenteral Fill/FinishAdvertisement
Related to this article
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Bill Williams, AAPS, compares KinetiSol and spray drying for amorphous solid dispersions, covering 75% drug loading, pill burden, weakly basic drug release, and process limits.
Pauric Bannigan, Intrepid Labs, explains how physics-informed machine learning aids formulation and why regulators still want experimental data.
Pauric Bannigan, Intrepid Labs, explains where AI speeds formulation decisions, why data is the bottleneck, and how active learning trains models with far less data.
Stephanie Johnson, Pfizer, explains how off-platform triggers, single-owner risk registers, and traceable prior knowledge keep protein formulation programs on track.
Stephanie Johnson, Pfizer, discusses how platform formulations moved 2 Pfizer protein programs to IND in 8 months by redistributing, not removing risk.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
2
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
3
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
4
Formulation Risk Needs One Accountable Owner: AAPS PharmSci 360 2026
5